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ABSTRACT
SARS-CoV-2 is a highly transmissible virus that
spreads mainly via person-to-person contact
through respiratory droplets, or through con-
tact with contaminated objects or surfaces from
an infected person. At present we are passing
through a phase of slow and painful under-
standing of the origin, epidemiological profile,
clinical spectrum, and risk profile of the virus.
To the best of our knowledge there is only
limited and contradictory evidence concerning
SARS-CoV-2 transmission through other routes.
Importantly, the eye may constitute not only a
potential site of virus replication but also an
alternative transmission route of the virus from
the ocular surface to the respiratory and gas-
trointestinal tract. It is therefore imperative to
gain a better insight into the potential oph-
thalmological transmission route of the virus
and establish directions on best practice and
future models of care for ophthalmological
patients. This review article critically evaluates
available evidence on the ophthalmological
mode of viral transmission and the value of
earlier identification of the virus on the eye.
More evidence is urgently needed to better
evaluate the need for protective measures and
reliable ocular diagnostic tests to diminish fur-
ther pandemic spread.
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Key Summary Points
The presence of SARS-CoV-2 receptors in
the eye may explain the viral tropism to
the ocular tissue.
Although SARS-CoV-2 RNA has been
detected in tear and conjunctival
secretion specimens, accurate and
consistent detection of ophthalmic
involvement with conjunctival swaps
remains problematic.
Importantly, the virus load in RT-PCR
testing of tears and conjunctival samples
often lies below detection threshold and
consequently testing shows low
sensitivity.
Future controlled studies are warranted to
evaluate the precise rate and role of ocular
involvement in SARS-CoV-2 infection.
The eye appears to play a key role in virus
replication and downstream transmission.
Therefore, better understanding and
detection of viral transmission from the
ocular surface to the respiratory and
gastrointestinal tract are key topics of
future research.
Personal protective equipment, including
eye wear protection, is recommended.
INTRODUCTION
A novel coronavirus epidemic caused by the
severe acute respiratory syndrome coronavirus-
2 (SARS-CoV-2) has spread to nearly every
country in the world since the virus first
emerged in China in December 2019. This virus
causes the coronavirus disease 2019 (COVID-
19), which has at the time of writing been
responsible for more than 10 million confirmed
cases and 500,000 global fatalities, and has had
an extraordinary socioeconomic impact world-
wide. At present we are going through a phase
of slow and painful understanding of the origin,
epidemiological profile, clinical spectrum, and
risk profile of the virus. SARS-CoV-2 is a highly
transmissible virus that spreads mainly through
person-to-person contact via respiratory dro-
plets, or through contact with contaminated
objects or surfaces from an infected person.
Evidence regarding SARS-CoV-2 transmission
through other routes, such as the fecal–oral
route and through the ocular surface is cur-
rently under investigation. At present, the sci-
entific evidence concerning ophthalmological
transmission of the virus is limited and, in
many cases, contradictory. It is therefore
imperative to gain a better insight into the
ophthalmological transmission route of the
virus and to establish directions on best practice
to plan future models of care for ophthalmo-
logical patients. We decided to critically review
available evidence on the ophthalmological
route of transmission and the value of earlier
identification of the impact of COVID-19 upon
the eye. The current work highlights the urgent
need to delineate optimal protective measures
and to evaluate the role of any potentially reli-
able future ocular diagnostic tests which could
prevent further pandemic spread.
METHODS
We reviewed the pertinent literature through
PubMed. A literature search was conducted
under the topics COVID-19; SARS-CoV-2;
transmission; eye; RT-PCR; tears; and conjunc-
tiva. Relevant references for papers related to
‘‘SARS-CoV-2/COVID-19, ocular transmission
and ophthalmology’’ published till 8 May 2020
were selected. The websites of the World Health
Organization (WHO), the Centers for Diseases
for Control and Prevention (CDC), the Ameri-
can Society of Ophthalmology, Spanish Society
of Ophthalmology, and American and Euro-
pean Societies of Cataract and Refractive Sur-
gery have been consulted. The literature search
was conducted by all the authors, who selected,
summarized, and agreed to the recommenda-
tions. This article is based on previously con-
ducted studies and does not contain any studies
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with human participants or animals performed
by any of the authors.
SARS-COV-2: GENERAL FEATURES
The new coronavirus SARS-CoV-2 belongs to
the same betacoronavirus family as the severe
acute respiratory syndrome coronavirus (SARS-
CoV) and the Middle East respiratory syndrome-
related coronavirus (MERS-CoV), which were
responsible for the outbreaks of severe acute
respiratory syndrome (SARS) in 2002 and 2012,
respectively [1, 2]. The genome of this envel-
oped positive-sense unsegmented single-strand
RNA virus is 29,891 nucleotides in size, encod-
ing 9860 amino acids. Overall, the genome of
SARS-CoV-2 has 89% nucleotide identity with
bat SARS-like-CoVZXC21 and 82% with that of
human SARS-CoV [3]. Viral genomic features
are currently under intense scientific scrutiny in
order to determine optimal diagnostic and
therapeutic strategies for this emerging health
threat.
Although the aforementioned viruses were
also highly transmissible, the SARS-CoV-2 has
spread more rapidly than its predecessors owing
to a combination of extensive globalization of
the economy and worldwide travel and the
characteristics of the organism. This had led to a
major global healthcare problem with severe
global economic repercussions and a marked
international recession.
ROLE OF THE EYE IN SARS-COV-2
TRANSMISSION
Unquestionably one of the most powerful
potential tools to slow the spread of the virus is
to deepen current knowledge of its transmission
routes. SARS-CoV-2 spreads primarily through
respiratory droplets and through contact with
contaminated objects or surfaces from an
infected person. There is more limited evidence
regarding SARS-CoV-2 transmission through
other routes, such as the fecal–oral route, which
relies upon the detection of the virus in differ-
ent types of tissue and fluids, including sputum,
blood, and feces [4]. Moreover, SARS-CoV-2 has
been detected in the tears and in conjunctival
specimens collected from infected patients,
suggesting that the ocular surface and the tears
might represent a potential route for SARS-CoV-
2 infection [5, 6]. Epidemiological evidence
supports this theory. A multicenter study which
documented potential risk factors for SARS-
CoV-2 transmission in patients requiring intu-
bation [7] reported that unprotected eye contact
with secretions from infected patients was the
most predictive variable for transmission to
healthcare workers. This observation high-
lighted the importance of using protective eye-
wear as an integral part of personal protective
equipment to avoid infection. A similar case
was reported earlier this year, when a doctor
working in Wuhan, who wore an N95 mask, but
did not wear eye protection, was subsequently
infected with SARS-CoV-2 and presented with
marked conjunctival hyperemia, suggesting
that unprotected exposure of the eyes to SARS-
CoV-2 might be a route for disease transmission
[8].
OCULAR MANIFESTATIONS
IN PATIENTS WITH COVID-19
Cumulative evidence suggests that SARS-CoV-2
infection can cause conjunctivitis, either as an
early sign of the infection or during hospital-
ization for COVID-19. The frequency of con-
junctivitis in patients with COVID-19 has not
been accurately quantified to date with reports
indicating markedly variable prevalence. A
study analyzing a sample of 1099 patients hos-
pitalized for COVID-19 disease in China repor-
ted conjunctivitis symptoms in only 0.8% of
afflicted patients (see Fig. 2 in [9]). In contrast,
Wu and co-workers [10] reported a prevalence
of conjunctival involvement as high as 31.6%.
The ocular symptoms related to COVID-19 are
in most cases non-specific and resemble those of
other forms of viral conjunctivitis. Recently, we
evaluated the clinical characteristics of con-
junctivitis in 14 Spanish patients with COVID-
19 [11]. Nearly half of them presented with
signs of unilateral conjunctivitis. Overall, 11
patients (79%) demonstrated mild ocular
hyperemia and in 8 patients (57%) moderate
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secretions were observed. None of our patients
showed conjunctival petechiae, corneal infil-
trates, membranes, or pseudomembranes,
which may be found in other forms of con-
junctivitis (e.g., adenoviral conjunctivitis).
None of the Spanish patients experienced
decreased vision and the mean duration of the
conjunctivitis was 3 days (range 1–7 days).
The presence of ocular pathology other than
conjunctivitis in patients with SARS-CoV-2
infection has yet to be described. Yuen et al. [12]
evaluated 45 patients during the epidemic out-
break of SARS in Hong Kong and did not
observe any ocular manifestations. However,
retinal disorders such as retinal vasculitis, reti-
nal degeneration, and blood–retinal barrier
breakdown have all been reported in experi-
mental animal models of coronavirus infection
[13, 14]. Moreover, it is important to highlight
that SARS-CoV-2 infection appears to predis-
pose patients to thrombotic disorders [15].
Therefore, the appearance of ocular vascu-
lar thrombotic events as a possible complication
of the disease cannot be ruled out at this
moment.
OCULAR TROPISM
AND RECEPTORS FOR SARS-COV-2
The viral tropism to the ocular tissue could be
partially explained by the presence of receptors
for SARS-CoV-2 in the eye. The mechanism of
SARS-CoV-2 cell entry depends on the viral
spike S proteins binding to cellular receptors
and on S protein priming by host cell proteases.
With regard to virus receptors, SARS-CoV-2
appears to employ angiotensin-converting
enzyme 2 receptor (ACE2) for entry and trans-
membrane serine protease 2 (TMPRSS2) for
S protein priming [16]. These receptors for
SARS-CoV-2 have been identified in a wide
range of human tissues, including lungs, small
intestine, brain, kidney, and blood vessels
among others [17]. Importantly, ACE2 and
TMPRSS2 receptors have been identified in the
eye not only on the ocular surface (cornea and
conjunctiva) but also in deeper intraocular tis-
sues, such as retina and choroid [18, 19].
A recent study has established that the
expression level of these receptors in the con-
junctiva is significantly higher than that in the
cornea [18]. However, ACE2 expression levels
on the ocular surface tissues are lower than
those documented in the lung or the brain.
Moreover, the binding capability of ACE2 pro-
tein on conjunctival and corneal epithelial cells
to the spike proteins of SARS-CoV has been
shown to be inferior to that of the lung [20].
OCULAR SURFACE DEFENSE
MECHANISMS
The eye possesses mechanical, immunological,
and anatomical defense mechanisms [21].
Mechanical barriers comprise the eyelids and
eyelashes, as well as the tight intercellular
junctions of the corneal epithelium and con-
junctival mucosa. Moreover, tears contain
antimicrobial proteins such as lactoferrin and
immunoglobulins. Lactoferrin can inhibit the
binding of SARS-CoV to ACE2, and tear IgA has
proven to provide an effective immune defense
against different kinds of viruses [22, 23].
The lacrimal drainage system acts as a phys-
ical self-cleaning system that clears pathogens
from the ocular surface. However, this mecha-
nism may prove counterproductive for SARS-
CoV-2 infection, since passage of infected tears
through the nasolacrimal drainage system may
serve as an entry route of the virus from the
infected ocular surface to the respiratory and
digestive tract [24]. The opposite passage of the
virus from the nasal and oral mucosa to the eye
seems less likely, but cannot be ruled out
entirely.
A recent study evaluated the ocular tropism
of SARS-CoV-2 in patients with confirmed
COVID-19. Of the 56 subjects investigated there
was only one patient who gave a history of prior
pterygium surgery, with conjunctivitis and a
positive PCR result from the conjunctival swab
highlighting the importance of an intact ocular
surface in resisting virus invasion [25]. These
data could explain the virus’ ocular tropism and
account for the limited ocular involvement in a
healthy eye.
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VALUE OF SARS-COV-2 RNA
DETECTION IN TEARS
AND CONJUNCTIVAL SECRETIONS
There is good evidence for the presence of SARS-
CoV-2 RNA in the tears of patients with COVID-
19 and conjunctivitis [5, 9]. Interestingly,
reports describing the presence of the virus in
tears and conjunctival secretions from patients
with conjunctivitis did not detect the virus in
patients without conjunctivitis. However,
another study from Wuhan comprising 63
subjects with confirmed COVID-19 found that
the only patient with conjunctivitis exhibited a
negative conjunctival swab for SARS-CoV-2
RNA, whereas one patient without conjunc-
tivitis had a positive conjunctival swab [26].
Undoubtedly, the most appropriate labora-
tory test for an accurate SARS-CoV-2 diagnosis is
real-time polymerase chain reaction (RT-PCR) of
a nasopharyngeal specimen [27]. Overall, this
test demonstrates high specificity, and its sen-
sitivity depends on the specimen and the time
of testing during the course of the disease.
Importantly, RT-PCR has also been used to
detect viral nucleic acid in conjunctival sam-
ples. Our research team from Hospital Clinico
San Carlos, Madrid, Spain collected conjuncti-
val swab samples from 36 patients with labora-
tory-confirmed COVID-19. Of those, 18 patients
exhibited conjunctivitis and 18 did not. SARS-
CoV-2 RNA was detected in the conjunctival
swab of two patients (5.5%). Among the 18
patients with conjunctivitis, only one (5.5%)
showed a positive result. Likewise, SARS-CoV-2
RNA was detected in only one patient without
conjunctivitis (5.5%) [28]. Therefore, our study
revealed the same rate of positive results
amongst the group with and without conjunc-
tivitis, suggesting that detecting SARS-CoV-2 in
ocular fluids is not dependent upon the clinical
presence of conjunctivitis.
However, this extremely low positive rate of
SARS-CoV-2 RNA test by RT-PCR in tears and
conjunctival secretions from patients with lab-
oratory-confirmed SARS-CoV-2 infection raises
several doubts for its implementation. Firstly,
the viral load in the conjunctival sample may
prove to be insufficient for successful RT-PCR
detection of the virus. The viral load obtained
with a conjunctival specimen has been consis-
tently shown to be less than that from a
nasopharyngeal sample [9]. Therefore, it is
possible that the viral load does not reach the
threshold of detection of the virus, which could
explain RT-PCR’s low sensitivity in detecting
SARS-CoV-2 RNA in tears and conjunctival
secretions. Indeed, a recent paper by Zhou et al.
[29] found that the proportion of positive
results from conjunctival SARS-CoV-2 swabs
was only 2.5% (only 3 patients from a cohort of
121 patients with confirmed COVID-19 tested
positive for SARS-CoV-2 RNA with conjunctival
swabs). This disconcerting finding is consistent
with other studies that have reported a rela-
tively low likelihood of detecting the virus from
tear specimens of patients with COVID-19 [30].
Table 1 summarizes the relevant published
articles which report RT-PCR results from tears
and conjunctival secretions.
Since RT-PCR testing is highly specific, but
appears to lack sufficient sensitivity, negative
test results could in fact be false negative and
thus may not exclude the presence of the virus.
In this context it is noteworthy that sensitivity
can be improved if multiple specimens are col-
lected. A study by Xia et al. [5] tested tear and
conjunctival secretions twice at an interval of
2–3 days and the results showed better detec-
tion and good consistency. However, it should
be noted that limited resources and inadequate
clinical access to patients with COVID-19 by
and large limit the possibility of collecting
multiple samples.
On the other hand, it is possible that the
virus is only present in the tears and conjunc-
tival secretions for a brief period of the disease
duration, and thus the negative results may be
due to incorrect timing of sample collection. A
recent experimental study on rhesus macaques
confirmed the short-lived presence of the virus
in tears after conjunctival inoculation, indicat-
ing that although the virus-containing fluid can
be found in ocular tissues, the majority of this
fluid is drained into the nasopharyngeal space,
or swallowed [31].
Another factor that may influence the neg-
ative results of conjunctival swabs is the stage of
the disease at which the conjunctival sample is
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collected. In a study by Chan et al. [32], tears
swabs and conjunctival scrapings tested positive
for SARS-CoV only when collected during the
early stage of the infection, whereas the results
were negative when specimens were collected at
a later stage of the disease. In contrast, a case
report of a 30-year-old man, who developed
conjunctivitis on day 13 of the infection,
demonstrated positive conjunctival swabs for
SARS-CoV-2 over a period of 5 days until day 18
of his illness [9]. Similarly, in a case from Italy,
SARS-CoV-2 RNA was detected in conjunctival
secretions up to day 21 following hospital
admission, and then 5 days after it became
undetectable, but the virus was detected again
in the ocular swab sample collected at day 27
[33].
PROTECTIVE MEASURES AGAINST
SARS-COV-2: DO WE NEED
EYEWEAR PROTECTION?
Despite ocular complications not being a com-
mon clinically detectable manifestation of
SARS-CoV-2 infection, recent evidence suggests
that ocular exposure may represent a major
transmission route for the virus. Thus, the eye
not only constitutes a potential site of virus
replication but more alarmingly also an insidi-
ous route for the transmission of the virus from
the ocular surface to the respiratory and gas-
trointestinal tract. These findings highlight the
relevance of appropriate use of personal pro-
tective gear for all healthcare personnel,
including eye wear protection as a integral part
of safety procedures against virus
contamination.
RISK OF SARS-COV-2
TRANSMISSION THROUGH
OPHTHALMIC PROCEDURES
As a direct result of the pandemic, the health-
care burden of patients without COVID-19 has
been reduced, and only urgent ophthalmologi-
cal procedures are performed in many coun-
tries. As a result of the proximity needed for
ophthalmological examination and the
Table 1 Summary of published articles presenting RT-PCR results from tears and conjunctival secretions
References Journal Number of
cases
RT-PCR1 in
tear and
conjunctival
samples
Proportion
of RT-
PCR1
Conjunctivitis
ocular
symptoms
Patients with
conjunctivitis and
positive RT-PCR
Wu et al.
[9]
JAMA
Ophthalmology
28 2 7.1% 11 (39.2%) 2 (7.1%)
Zhou et al.
[29]
Ophthalmology 121 3 2.5% 8 (6.6%) 1 (0.8%)
Xia et al.
[5]
J. Medical
Virology
30 (2 samples
separated
2–3 days per
eye)
1 (2 samples
from the same
patient)
3.3% 1 (3.33%) 1 (3.3%)
Zhang
et al. [6]
MedRxiv 72 1 1.3% 2 (2.78%) 1 (1.3%)
Gu¨emes-
Villahoz
et al.
[28]
J. Medical
Virology
36 2 5.5% 18 (50%) 1 (5.5%)
N number of patients with positive RT-PCR form nasopharyngeal swabs, RT-PCR real-time polymerase chain reaction
Adv Ther
unavoidable exposure to tears and ocular dis-
charge during the exam, ophthalmologists are
high-risk personnel for SARS-CoV-2 infection.
Many ophthalmic instruments such as gonio-
scopy and laser lenses as well as ophthalmic
ultrasound probes require direct or close contact
with patients, which presumably increases the
risk of viral transmission. A non-contact
tonometer may create an aerosol when mea-
suring intraocular pressure by punching air
onto the cornea of patients; hence, it may also
facilitate virus spread by aerosol transmission
[34].
Moreover, since SARS-CoV-2 has been
detected in tears and ocular fluids [11, 28],
nasolacrimal duct syringing, probing, and
intubation, which can cause splashing of tears
and nasolacrimal secretions, may be considered
aerosol-generating procedures [35]. In fact,
many intraocular surgical procedures have been
deemed aerosol-generating procedures. As such,
endoscopic dacryocystorhinostomy should be
classified as a high-risk procedure [36, 37].
Aerosol generation has been evaluated during
phacoemulsification and suggestions have been
made to minimize visible aerosol production by
using a 2.2-mm phacoemulsification tip and
reapplying hydroxypropyl methylcellulose
(HPMC) coating of the cornea every minute
during phacoemulsification [38]. Another study
revealed that phacoemulsification did not gen-
erate aerosols of 10 lm or smaller with contin-
uous power using 80% longitudinal, 100%
torsional, or 80% longitudinal setting with
HPMC on the surface [39]. Visible aerosol gen-
eration during vitrectomy surgery has been also
evaluated using a physical model, although this
study did not find evidence of visible aerosol
generation during simulated vitrectomy surgery
[40].
Likewise, lasers, electrical cutting, and coag-
ulation systems during surgery may generate an
aerosol [41, 42]. Therefore, it is essential to
adjust the equipment, surgical techniques, and
work protocols to diminish the risk of exposure
as much as possible. A modification in the
design of the surgical fields as well as the use of
three-dimensional display systems for oph-
thalmic surgery may increase the physical dis-
tance between surgeon and patient.
Several ophthalmological societies, such as
the American Society of Ophthalmology, the
American and European Societies of Cataract
and Refractive Surgery, and the Spanish Society
of Ophthalmology have issued a series of rec-
ommended standard operating protocols on the
protective measures to be employed that have
been updated with emerging evidence. All agree
that it is safest to assume that any ophthalmic
patient is potentially at risk of having been
infected with SARS-CoV-2, especially in regions
currently facing significant outbreaks of
COVID-19. Overall, the recommended proto-
cols include access control systems with interim
guidance for triage, physical distancing mea-
sures, frequent and meticulous disinfection of
common areas and equipment, the use of slit
lamp barriers, or breath shields, a surgical mask
for the patient, and personal protective equip-
ment, including eye protection for healthcare
personnel [43]. The role of telemedicine during
the epidemic is also valuable in diminishing
risk. Ideally, necessary surgery should be per-
formed only after a negative diagnostic test for
SARS-CoV-2 with PCR prior to surgery for
patients and operating room staff alike, as well
as requesting a signed informed consent from
the patient explaining the risks arising from
SARS-CoV-2 infection.
CONCLUSION
SARS-CoV-2 is a highly contagious virus that
causes significant morbidity and mortality
worldwide. Understanding its transmission
routes is essential to reducing further spread of
the pandemic. The eye appears to play a role in
virus replication and downstream transmission.
Accurate and consistent detection of oph-
thalmic involvement with conjunctival swabs
remains problematic and variable since the
virus load can remain below the threshold of
detection and the timing of taking the swab
sample is critical. Better understanding and
detection of viral transmission from the ocular
surface to the respiratory and gastrointestinal
tract is required. Further large controlled studies
are warranted to evaluate the precise rate and
role of ocular involvement in SARS-CoV-2
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infection. The clinical value of tear and con-
junctival testing and the risk of infection for
ophthalmic personnel requires further
elucidation.
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